ECG Devices Market Segmentation:
End user Segment Analysis
Based on end user hospitals & clinics segment is expected to garner the largest revenue share of 52.6% in the ECG devices market during the discussed timeframe. The subtype remains as the primary center of care for cardiac diagnosis, surgery, and emergency care, which requires high-volume advanced ECG devices. The increasing global occurrence of cardiovascular deaths is necessitating early diagnosis; hence, this growing demand is driving significant investments in this field to improve patient outcomes.
Lead Type Segment Analysis
In terms of lead type, the 12-lead ECG devices segment is projected to attain a lucrative share of 45.3% in the ECG devices market during the analyzed timeframe. The view of the heart’s electrical activity from 12 different angles, offering superior diagnostic information, is the key factor behind the leadership. Clario in June 2024 reported that its SpiroSphere platform, integrated with the wireless COR‑12 ECG device, has received FDA 510(k) clearance, which streamlines workflows and improves the experience for both patients and trial sites.
Product Segment Analysis
Based on product, resting ECG systems are predicted to gain a share of 38.6% in the ECG devices market during the analyzed timeframe. The growth in the segment originates from its role as a first-line diagnostic tool for assessing heart rhythm and detecting abnormalities such as arrhythmias, ischemia, and past myocardial infarction. In June 2024, Fukuda Denshi announced the launch of its FX-9800 resting ECG and EFS-1000 data management system, which possesses 18-lead synthesis for enhanced detection of Acute Coronary Syndrome and is especially designed for ERs and ICUs.
Our in-depth analysis of the market includes the following segments:
|
Segment |
Subsegments |
|
End user |
|
|
Lead Type |
|
|
Product |
|
|
Technology |
|
|
Age Group |
|
